PRE- AND POST-TRANSPLANT ISSUES IN BLOOD AND MARROW TRANSPLANT
A MEETING OF THE CANADIAN BLOOD AND MARROW TRANSPLANT GROUP

CORPORATE PROGRAM
ADCETRIS, please refer to Health Canada’s Notice of Compliance with conditions – drug products website:

Consider ADCETRIS® for your patients for debilitating diseases that are often difficult to diagnose.

FOCUSED ON DEVELOPING SPECIALTY TREATMENTS for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

www.sanofigenzyme.com
We will change what a cancer diagnosis means. Together.

At Janssen, we’re not about small steps. We’ve set our sights on making cancer a preventable and curable disease. This isn’t easy. That’s why we partner with the world’s top minds, from academic institutions and patient advocates to companies large and small.

Together, we are working toward one goal: changing what a cancer diagnosis means for patients and their loved ones.

We bring to life transformational cancer therapies – with a commitment to help get them to the people who need them.

We are Janssen. We collaborate with the world for the health of everyone in it.

Learn more at www.janssen.com/canada
SPONSOR AND EXHIBITOR LISTING

We would like to thank the sponsors of the Canadian Blood and Marrow Transplant Group Themed Meeting “Pre- and Post-Transplant Issues in BMT”; the conference is made possible through the generous support of the following companies:

<table>
<thead>
<tr>
<th>Platinum Sponsors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janssen</td>
</tr>
<tr>
<td>Sanofi Genzyme</td>
</tr>
<tr>
<td>Seattle Genetics</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gold Sponsors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Celgene</td>
</tr>
<tr>
<td>Lundbeck</td>
</tr>
<tr>
<td>Oncology</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Silver Sponsors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jazz Pharmaceuticals</td>
</tr>
<tr>
<td>Otsuka</td>
</tr>
<tr>
<td>Pfizer Oncology</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bronze Sponsors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roche</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Meeting Supporters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paladin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symposia Supporters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jazz Pharmaceuticals</td>
</tr>
<tr>
<td>Lundbeck</td>
</tr>
<tr>
<td>Oncology</td>
</tr>
<tr>
<td>Merck</td>
</tr>
<tr>
<td>Seattle Genetics</td>
</tr>
</tbody>
</table>
# TABLE OF CONTENTS

- Sponsor and Exhibitor Listing ................................................................. 4
- Corporate Program .................................................................................. 6
- Sponsored Symposium Information ......................................................... 7
- Sponsor Descriptions ............................................................................. 10
- About CBMTG .......................................................................................... 12
- Upcoming Webinars ................................................................................ 14
CORPORATE PROGRAM

Friday, September 8, 2017

7:00am – 8:45am
Bannerman 1, 3

Breakfast Symposium

Addressing the Transplant Ineligible and Transplant Eligible Mantle Cell Lymphoma (MCL) Patients: New Approaches to Disease Management

12:15pm – 1:45pm
Bannerman 1, 3

Lunch Symposium

How is the Landscape of Classical Hodgkin Lymphoma Therapy Changing

Saturday, September 9, 2017

7:00am – 8:45am
Bannerman 1, 3

Breakfast Symposium

Cytomegalovirus Infection in Your Hematology Patient – What’s Standard, What’s New?

12:15pm – 1:45pm
Bannerman 1, 3

Lunch Symposium

Post BMT Complications: A New Dawn in Veno-Occlusive Disease (VOD)? A revised Risk Stratification and Diagnostic Criteria in a Serious Complication of HSCT
SPONSORED SYMPOSIUM

Friday, September 8, 2017

Breakfast Symposium

Addressing the Transplant Ineligible and Transplant Eligible Mantle Cell Lymphoma (MCL) Patients: New Approaches to Disease Management

Speakers:
Carlo Visco, MD, San Bortolo Hospital, Vicenza, Italy
Cindy Toze, MD, MHSc, FRCP, ABIM, Leukemia/BMT Program of BC, Vancouver, BC, Canada

Learning Objectives:
1. Identify new approaches to further optimize the Canadian standard of care
2. Answer concerns related to new approaches in the transplant ineligible and eligible MCL patients

Lunch Symposium

How is the Landscape of Classical Hodgkin Lymphoma Therapy Changing

This symposium will provide a review of currently available treatment options for Hodgkin Lymphoma patients as well as look forward to future options for patients. Patient cases will be reviewed.

Chair:
Stephen Couban, MD, FRCP, Dalhousie University, Halifax, NS, Canada

Speaker:
John Sweetenham, MD, FRCP, FACP, Huntsman Cancer Hospital, Salt Lake City, UT, United States

Learning Objectives:
1. Review of current and future treatment options for Hodgkin Lymphoma patients
Cytomegalovirus Infection in Your Hematology Patient – What’s Standard, What’s New?

Led by a panel of Canadian speakers, this symposium will address current strategies around the management, prevention and treatment of cytomegalovirus (CMV) infection/disease in hematopoietic stem cell transplant (HSCT) patients. Speakers will define CMV infection and disease, and describe its epidemiology and burden in Canadian HSCT patients. Risk factors will be identified, and the challenges associated with CMV will be illustrated with a focus on the perspective of hematological oncologists. Relevant, real-world case studies will be used to highlight treatment challenges and both advantages and disadvantages of preemptive and prophylactic strategies. Speakers will then discuss current and forthcoming options for the prevention and treatment of CMV disease in HSCT patients.

Speakers:

Stephen Couban, MD, FRCP, Dalhousie University, Halifax, NS, Canada
Shariq Haider, MD, FRCP, FACPE, DTMH CCST (Internal Medicine, UK), McMaster University, Hamilton, ON, Canada
Kylie Lepic, MD, McMaster University, Hamilton, ON, Canada

Learning Objectives:

1. Recognize burden of illness, risk factors for, and complications associated with CMV infection and disease in HSCT patients
2. Discuss contemporary challenges in the management of patients with CMV, from the perspective of hematologist-oncologists
3. Describe current and future approaches to the prevention and treatment of CMV infection and disease in HSCT patients
Saturday, September 9, 2017

Lunch Symposium

Post BMT Complications: A New Dawn in Veno-Occlusive Disease (VOD)? A revised Risk Stratification and Diagnostic Criteria in a Serious Complication of HSCT

It gives us great pleasure to welcome you to this lunch symposium supported by Jazz Pharmaceuticals: “Post BMT Complications: A New Dawn in Veno-occlusive disease (VOD)?”, taking place at St. John’s CBMTG meeting.

Patients who have undergone hematopoietic cell transplantation (HCT) can face significant and often life-threatening complications throughout the recovery process. We will discuss the critical tasks of diagnosing and managing veno-occlusive disease (VOD) in the context of the revised EBMT diagnosis and severity grading criteria. The session will feature interactive, real-life case studies illustrating the crucial issues of VOD: risk factors, timing of onset, diagnosis, severity grading and effective management; including the new EBMT pediatric diagnosis and severity criteria for VOD.

We are sure this will prove to be a thought-provoking and insightful session, providing practical insights and expert opinion on the effective management of VOD.

Speakers:
Jean-Hugues Dalle, MD, PhD, Robert Debré Hospital, Paris, France
Irwin Walker, MBBS, FRACP, FRCPC, McMaster University, Hamilton, ON, Canada

Learning Objectives:
1. Educate on new EBMT Diagnosis and Severity grading for VOD for Adults
2. Educate on new EBMT Diagnosis and Severity grading for VOD for Pediatrics
3. Risk stratification in practice
4. Treatment of severe Veno-occlusive Disease (sVOD): How, what, when and for how long?
5. VOD case study
SPONSOR DESCRIPTIONS

Celgene, Inc.

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide.

Celgene Inc., a wholly-owned subsidiary of Celgene Corp., established its presence in Canada in 2006 and is located in Mississauga, Ontario.

At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin’s lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer.

Janssen, Inc.

Janssen Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson, which are dedicated to addressing and solving some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world. For more information please visit: http://www.janssen.com/canada/.

Jazz Pharmaceuticals

Jazz Pharmaceuticals PLC, a specialty biopharmaceutical company that identifies, develops and commercializes medicines in focused therapeutic areas related to haematology-oncology and haematopoietic stem cell transplantation. We are dedicated to help make a difference in patients’ lives through our innovative medicines, passion, collaboration and pursuit of excellence.

Lundbeck Canada Inc.

Montreal-based Lundbeck Canada is a subsidiary of H. Lundbeck A/S, a leading international research-based pharmaceutical company. Globally, we have been around for 100 years, and 20 years in Canada. We take pride in the progress we’ve made in mental health and oncology. We’re now focusing on the next generation of healthcare advancements, because, for us, it’s all about helping Canadians lead better lives. Visit us at lundbeck.ca.

Merck Canada Inc.

For over a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers to deliver innovative health solutions. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease, and infectious diseases including HIV and ebola. For more information, visit www.merck.ca.

Otsuka Canada Pharmaceutical Inc.

People creating new products for better health worldwide: Otsuka Canada Pharmaceutical Inc. (OCPI) is an innovative, fast-growing health care company that commercializes Otsuka medicines in Canada, with a focus on and commitment to neuroscience, cardiovascular, nephrology and oncology. OCPI is dedicated to improving patients’ health and the quality of human life. OCPI is part of the Otsuka Group, and was established in 2010, with headquarters in Technoparc Montreal, in Saint-Laurent, Quebec.
Paladin Labs
Paladin Labs is a specialty pharmaceutical company, and member of Rx&D, focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market & select international markets.

Pfizer Canada Inc.
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., one of the world’s leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world’s best known and most prescribed medicines, infusion systems and vaccines. At Pfizer, we’re working together for a healthier world. To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on Twitter (twitter.com/PfizerCA) or Facebook (facebook.com/Pfizer.Canada).

Roche Canada
From our approach to clinical trials for new drug therapies, to industry partnerships and community involvement, Roche Canada is a leader in providing pharmaceutical and diagnostic solutions that make a profound difference in people’s lives. Our innovative approach improves the effectiveness and efficiency of the healthcare system in the diagnosis, treatment and management of acute and long-term disease. Roche Canada employs approximately 1,000 people across the country, with its pharmaceuticals head office located in Mississauga, Ontario and diagnostics division based in Laval, Quebec. We serve a broad base of healthcare facilities and practitioners across the country, working in partnership with them to ensure that the diagnostics and therapies we deliver meet the medical needs of today and of the future.

Sanofi Genzyme
Sanofi Genzyme, the Specialty Care Global Business Unit of Sanofi, is committed to helping people with debilitating and complex diseases. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Please visit www.Genzyme.ca for more information.

Seattle Genetics, Inc.
Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents to cancer cells. The company’s lead product, ADCETRIS® (brentuximab vedotin) is a CD30-targeted ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available in more than 60 countries worldwide, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 70 ongoing clinical trials in CD30-expressing malignancies. Seattle Genetics is also developing a robust pipeline of more than a dozen other clinical and preclinical programs, and has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies. Find more information at www.seattlegenetics.com.
ABOUT CBMTG

The Canadian Blood and Marrow Transplant Group (CBMTG) is a national, voluntary, and multi-disciplinary organization providing leadership and promoting excellence in patient care, research, and education in the field of BMT.

CBMTG’s vision is that Canada will be the best place in the world to have a blood and marrow transplant, and our mission is to be the voice of experts working in the field of blood and marrow transplant.

The CBMTG values: excellence, innovation, integrity, collaboration, and professionalism in care, education, and research in blood and marrow transplant. CBMTG believes that every patient has a right of equal access to the highest quality of life saving care that can be provided by blood and marrow transplant professionals in Canada.

Based on this, our strategic priorities are as follows:

Education
Provide high quality educational programs that advance the practice of blood and marrow transplantation in Canada.

Research
Establish and organize an effective and sustainable research infrastructure for translational and clinical research.

Outreach
Increase the visibility and influence of CBMTG among members and the public.

Financial Capacity
Support, education, research, and outreach initiatives through fundraising, partnerships, and the establishment of a charitable organization.

CBMTG Membership:

The CBMTG membership is made up of national and international physicians, nurses, laboratory technicians, pharmacists, and coordinators working in blood and marrow transplant.

FOR MORE INFORMATION, PLEASE VISIT WWW.CBMTG.ORG.
Malachite is proud to provide professional management services to the Canadian Bone and Marrow Transplant Group since 1999.

Your Complete BMT Software Solution
Request a demo at stemsoft.com
DON'T MISS THESE UPCOMING WEBINARS

WEDNESDAY, SEPTEMBER 27, 2017
12:00PM ET/9:00AM PT
*Please note this webinar is hosted by one of our sponsors.

The Changing Picture of Transplant Complications: A European Perspective on Veno-Occlusive Disease (VOD)
Rafael Duarte, MD, PhD

LEARNING OBJECTIVES:
1. Understand the use of revised VOD diagnostic criteria and risk stratification in clinical practice
2. Understand the clinical evidence for efficacy and safety of treatment for VOD
3. Review practical management of patients with severe transplant complications

WEDNESDAY, OCTOBER 18, 2017
12:00PM ET/9:00AM PT
CME CREDIT HOURS: 1.0

Ocular Chronic GVHD
Vikas Sharma, PhD

WEDNESDAY, NOVEMBER 1, 2017
12:00PM ET/9:00AM PT
*Please note this webinar is hosted by one of our sponsors.

The Nurse’s Role in the Management of Acute Transplant Complications
John Murray, Nurse Clinician

LEARNING OBJECTIVES:
1. Recognize complications of transplantation, and how to provide supportive care
2. Understand the potential causes of GVHD/Veno occlusive disease and its pathophysiology
3. Review the clinical presentation and how to grade Veno occlusive disease
4. Review the nursing care and input required and how this is a vital aspect

WEDNESDAY, NOVEMBER 15, 2017
1:00PM ET/10:00AM PT
CME CREDIT HOURS: 1.0

Quality and Accreditation
Denise Brophy

WEDNESDAY, DECEMBER 6, 2017
3:00PM ET/12:00PM PT
*Please note this webinar is hosted by one of our sponsors.

Invasive Fungal Infections in High-Risk Patients: When Early Might not be too Early and When Late, Might be too Late

LEARNING OBJECTIVES:
1. Recognize burden of illness in Canada, risk factors for, and complications of invasive fungal infection (IFI)
2. Outline optimal treatment strategies for the management of IFI while applying latest clinical practice guidelines
3. Share real life experience with mold-active prophylaxis in high risk patients

VISIT WWW.CBMTG.ORG TO REGISTER AND FOR MORE MEMBERSHIP INFORMATION

MEMBERS PRICE: FREE
NON-MEMBERS PRICE: $90 + 5% GST

This event is an Accredited Group Learning Activity eligible for up to 10.0 MOC Section 1 credits as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. This program has been reviewed and approved by UBC Division of Continuing Professional Development. Each physician should claim only those credits he/she actually spent in the activity.
We invite all blood and marrow transplant health care professionals to attend our annual meeting in Ottawa in 2018.

The 2018 conference planning committee, led by Dr. David Allan and Dr. Natasha Kekre, will work to create an exciting program that will include scientific plenary sessions, keynote presentations, multi-disciplinary and discipline-specific sessions, oral and poster abstract presentations, committee and society meetings, and corporate satellite symposia. We hope you will attend!